Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2019 Mar 1;80(3):308-315.
doi: 10.1097/QAI.0000000000001921.

Early and Late Virologic Failure After Virologic Suppression in HIV-Infected Asian Children and Adolescents

Affiliations
Multicenter Study

Early and Late Virologic Failure After Virologic Suppression in HIV-Infected Asian Children and Adolescents

Weiwei Mu et al. J Acquir Immune Defic Syndr. .

Abstract

Background: Virologic failure is a major threat to maintaining effective combination antiretroviral therapy, especially for children in need of lifelong treatment. With efforts to expand access to HIV viral load testing, our understanding of pediatric virologic failure is evolving.

Setting: An Asian cohort in 16 pediatric HIV services across 6 countries.

Methods: From 2005 to 2014, patients younger than 20 years who achieved virologic suppression and had subsequent viral load testing were included. Early virologic failure was defined as a HIV RNA ≥1000 copies per milliliter within 12 months of virologic suppression, and late virologic as a HIV RNA ≥1000 copies per milliliter after 12 months following virologic suppression. Characteristics at combination antiretroviral therapy initiation and virologic suppression were described, and a competing risk time-to-event analysis was used to determine cumulative incidence of virologic failure and factors at virologic suppression associated with early and late virologic failure.

Results: Of 1105 included in the analysis, 182 (17.9%) experienced virologic failure. The median age at virologic suppression was 6.9 years, and the median time to virologic failure was 24.6 months after virologic suppression. The incidence rate for a first virologic failure event was 3.3 per 100 person-years. Factors at virologic suppression associated with late virologic failure included older age, mostly rural clinic setting, tuberculosis, protease inhibitor-based regimens, and early virologic failure. No risk factors were identified for early virologic failure.

Conclusions: Around 1 in 5 experienced virologic failure in our cohort after achieving virologic suppression. Targeted interventions to manage complex treatment scenarios, including adolescents, tuberculosis coinfection, and those with poor virologic control are required.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

There is no conflicts of interest.

Figures

Figure 1.
Figure 1.
Incidence of virologic failure for each year of combination antiretroviral therapy following virologic suppression. cART = combination antiretroviral therapy. VF = virologic failure.
Figure 2.
Figure 2.
Cumulative incidence of virologic failure following virologic suppression by age at combination antiretroviral therapy initiation. cART = combination antiretroviral therapy.

References

    1. World Health Organization. What’s New in Treatment Monitoring: Viral Load and CD4 Testing. July 2017. Available at: http://www.who.int/hiv/pub/arv/treatment-monitoring-info-2017/en/. Accessed 2 October 2018.
    1. The Joint United Nations Programme on HIV/AIDS. 90-90-90 An ambitious treatment target to help end the AIDS epidemic. October 2014. Available at: http://www.unaids.org/en/resources/documents/2017/90-90-90. Accessed 8 September 2017.
    1. Abrams EJ, Strasser S. 90-90-90--Charting a steady course to end the paediatric HIV epidemic. J Int AIDS Soc. 2015;18(Suppl 6):20296. - PMC - PubMed
    1. Bunupuradah T, Sricharoenchai S, Hansudewechakul R, et al. Risk of first-line antiretroviral therapy failure in HIV-infected Thai children and adolescents. Pediatr Infect Dis J 2015;34(3):e58–e62. - PubMed
    1. Davies MA, Moultrie H, Eley B, et al. Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration. J Acquire Immune Defic Syndr 2011;56(3):270–278. - PMC - PubMed

Publication types

Substances